Vimseltinib

Orphan DrugFDA Approved (2025)

Description

An oral CSF1R inhibitor for tenosynovial giant cell tumor not amenable to surgery. FDA-approved February 2025.

Indications & Therapeutic Use

Tenosynovial giant cell tumor

Linked Diseases:

Tenosynovial Giant Cell Tumor
2E80.Y

Evidence: FDA-approved indication

Global Availability (1 countries)

CountryAccess RouteRegulatory PathwayLead TimeStatus
Standard Marketing AuthorizationApproved

Available Through

This drug is available for procurement through the following fulfilment partner.

Fulfilment Partner
Vimseltinib
Generic Namevimseltinib
Brands1 brand available
Active Ingredientvimseltinib
Drug ClassTenosynovial giant cell tumor
ManufacturerDeciphera Pharmaceuticals
Orphan StatusYes — Orphan Drug
Cold ChainNot Required
Reg. StatusFDA Approved (2025)
Countries1 countries
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes